![mr058666-web](https://pharmafile.com/wp-content/uploads/2016/04/mr058666-web_5.jpg)
Merck appoints Maya Martinez-Davis as global head of oncology
pharmafile | April 14, 2016 | Appointment | Medical Communications | Merck, maya martinez-davis, oncology
Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company.
In her new role leading the Global Oncology Franchise, Martinez-Davis’ responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for Avelumab is expected in 2017
“Maya’s considerable experience in oncology, which includes the recent successful launch of Ibrance in the USA, make her a valued addition to our team as we endeavor to bring new therapeutic options to patients living with cancer,” said Rehan Verjee, chief marketing and strategy officer of Merck’s healthcare business sector. “This is a very exciting time for our company as we advance our promising oncology and immuno-oncology pipeline and attract leading industry talent to Merck.”
Prior to joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches.
Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.
Related Content
![](https://pharmafile.com/wp-content/uploads/2024/01/shutterstock_2154643979-300x200.jpg)
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored …
![brain_mri_131749_t1](https://pharmafile.com/wp-content/uploads/2020/10/brain_mri_131749_t1-270x300.png)
Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA
The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) …
![](https://pharmafile.com/wp-content/uploads/2023/08/nappy-5RDjrd5GXuM-unsplash-300x200.jpg)
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
Merck, known as MSD outside of the US and Canada, has announced that the US …